FY2025 Earnings Estimate for ARWR Issued By Leerink Partnrs

Key Points

• Leerink Partners has reduced its FY2025 earnings per share (EPS) estimate for Arrowhead Pharmaceuticals from $1.35 to $1.15, contrasting with the current consensus estimate of ($2.42) EPS.
• Various analysts have issued mixed ratings for Arrowhead Pharmaceuticals, with three giving a hold rating, six a buy rating, and one a strong buy rating, reflecting a consensus rating of Moderate Buy.
• The company's stock has a market cap of $2.27 billion and has shown significant volatility, with a 1-year low of $9.57 and a high of $27.34.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities researchers at Leerink Partnrs reduced their FY2025 EPS estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Tuesday, August 5th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings of $1.15 per share for the year, down from their previous forecast of $1.35. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals' Q4 2025 earnings at $0.86 EPS and FY2027 earnings at ($2.30) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same period last year, the business earned ($1.38) earnings per share.

ARWR has been the topic of several other reports. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Royal Bank Of Canada cut their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research report on Friday. Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Finally, TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $43.14.

Arrowhead Pharmaceuticals Stock Up 2.2%

ARWR traded up $0.36 during trading on Wednesday, hitting $16.42. The company had a trading volume of 2,806,298 shares, compared to its average volume of 2,030,270. The company has a market capitalization of $2.27 billion, a PE ratio of -12.83, a PEG ratio of 23.70 and a beta of 0.94. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $27.34. The firm's 50-day moving average price is $16.48 and its 200 day moving average price is $15.97. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 0.31.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Exchange Traded Concepts LLC lifted its position in Arrowhead Pharmaceuticals by 31.8% during the 1st quarter. Exchange Traded Concepts LLC now owns 49,247 shares of the biotechnology company's stock worth $627,000 after buying an additional 11,879 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth about $651,000. GAMMA Investing LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares during the period. New York State Teachers Retirement System raised its holdings in shares of Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. New York State Teachers Retirement System now owns 148,376 shares of the biotechnology company's stock valued at $1,890,000 after purchasing an additional 9,593 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 117.8% in the 1st quarter. Principal Financial Group Inc. now owns 629,075 shares of the biotechnology company's stock valued at $8,014,000 after purchasing an additional 340,191 shares during the period. 62.61% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.